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Background: Flexible dosing of anticholinergics used for overactive bladder (OAB) treatment is a useful strategy in
clinical practice for achieving a maximum effective and maximum tolerated level of therapeutic benefit. In this post
hoc analysis we evaluated the efficacy and tolerability of trospium chloride treatment for urinary urge incontinence
(UUI) with focus on flexible dosing.
Methods: The data came from a 12-week, randomised, double-blind, phase IIIb study in which 1658 patients with
urinary frequency plus urge incontinence received trospium chloride 15 mg TID (n = 828) or 2.5 mg oxybutynin
hydrochloride TID (n = 830). After four weeks, daily doses were doubled and not readjusted in 29.2% (242/828) of
patients in the trospium group, and in 23.3% (193/830) in the oxybuytnin group, until the end of treatment. We
assessed the absolute reduction in weekly UUI episodes and the change in intensity of dry mouth, recorded in
patients’ micturition diaries. Adverse events were also evaluated. Statistics were descriptive.
Results: Dose escalation of either trospium or oxybutynin increased reduction in UUI episodes in the population
studied. At study end, there were no relevant differences between the “dose adjustment” subgroups and the
respective “no dose adjustment” subgroups (trospium: P = 0.249; oxybutynin: P = 0.349). After dose escalation,
worsening of dry mouth was higher in both dose adjusted subgroups compared to the respective “no dose
adjustment” subgroups (P < 0.001). Worsening of dry mouth was lower in the trospium groups than in the
oxybutynin groups (P < 0.001). Adverse events were increased in the dose adjusted subgroups.
Conclusions: Flexible dosing of trospium was proven to be as effective, but better tolerated as the officially
approved adjusted dose of oxybutynin.
Trial registration (parent study): The study was registered with the German Federal Institute for Drugs and Medical
Devices (BfArM, Berlin, Germany), registration number 4022383, as required at the time point of planning this study.
Background
Antimuscarinics (e.g., trospium chloride, tolterodine, dari-
fenacin, oxybutynin) are effective in reducing detrusor
overactivity and hence urgency and urinary urge inconti-
nence (UUI). However, by virtue of their mechanism of
action the tolerability and usefulness of these drugs is
often diminished by relatively common and well-known
peripheral side effects. Optimal treatment should therefore
be individualised, considering the patient’s co-morbidities,
concomitant medications and the pharmacological profiles
of the different drugs [1-6].
Flexible dosing of anticholinergics is a common and use-
ful strategy in clinical practice for achieving a maximum
effective and maximum tolerated level of therapeutic
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any medium, provided the original work is properly cited.benefit [7-9]. Patients who are most responsive to the drug
can therefore receive the lowest effective dose; other
patients could achieve greater improvements in symptoms
and quality of life with a tailor-made dose adjustment. As
most patients with overactive bladder (OAB) symptoms
are elderly (65 years or older), considerations for safety
and compliance are of special importance. Although dose
escalation can be implemented with nearly all of the antic-
holinergics, it is done most often and approved with oxy-
butynin [9,10]. In the case of trospium chloride (TC)
urologists prescribe the drug in other, the recommended
daily dosage of 45 mg often exceeding doses for treatment
of UUI/OAB [11], especially in patients with neurogenic
detrusor overactivity [2,12]. However, to date dose escala-
tion of individual daily medication is not mentioned in the
SPC of trospium.
The noninferiority of trospium 45 mg per day in com-
parison to oxybutynin (OXY) 7.5 mg per day exploring
efficacy, tolerability and effects on health-related quality
of life parameters has previously been assessed in
patients with documented urinary frequency plus urge
incontinence in a large, 12-week, randomised, double-
blind, flexible-dose phase IIIb trial [13]. Daily dosages
could be increased upward after four weeks, to 90 mg of
trospium and 15 mg of oxybutynin, respectively, if
needed. The purpose of the present post hoc analysis
was to compare the effects and the tolerability of flexible
dosing in those patients stratified according to “dose
adjustment” and “no dose adjustment” subgroups. The
objective was not to evaluate “data driven” statistically
significant results, but to reveal detailed advice and
answers to the results of the study.
Methods
This is a post hoc analysis of data from a randomised,
double-blind, active-controlled, parallel-group, flexible-
dose phase IIIb trial conducted at 153 urological centres
in Germany; details of the study design and methods
were published previously [13]. The study was carried
out in accordance with the German Drug Law, the
Revised Declaration of Helsinki, and the European
Union standards of Good Clinical Practice. The inde-
pendent ethics committee of the Bavarian State Cham-
ber of Physicians (Munich, Germany) approved the
study protocol, the protocol amendment, the informa-
tion sheet, and the consent form before the start of the
study (reference number: 04075; Munich, 15 July 2004).
Patients
Eligibility for the study was determined by the comple-
tion of a 7-day micturition diary before randomisation.
Men and women (18 years of age or older) with urinary
frequency (eight or more micturitions every 24 hours)
plus urge incontinence (five or more episodes per week)
met the inclusion criteria.
Based on this first diary, subjects with a total daily
urine volume of 2.8 L or more, a mean micturition
volume of more than 250 mL, and/or a clinically signifi-
cant bladder outlet obstruction (i.e., postvoid residual
u r i n ev o l u m eo fm o r et h a n1 0 0m L )w e r ee x c l u d e d
from participation, as were those with an indwelling
catheter or intermittent self-catheterization; urinary
tract infection at the screening visit; interstitial cystitis
and/or hematuria; contraindications to anticholinergic
therapy (e.g., untreated narrow-angle glaucoma,
mechanical gastrointestinal stenosis, myasthenia gravis
syndrome), tachycardiac arrhythmia, severe psychiatric
illnesses, hypersensitivity to trospium or oxybutynin or
one of the vehicle ingredients; participation in a bladder
training or electrostimulation program, or in another
study within the past 30 days. Patients currently receiv-
ing drug treatment for UUI were allowed to enter the
s t u d yf o l l o w i n ga1 4 - d a yw a s h o u tp e r i o dp r i o rt os t u d y
treatment. Concomitant treatments (i.e., other anticholi-
nergic drugs or drugs possessing significant anticholi-
nergic or sympathomimetic effects) as well as drugs that
could interact with trospium or oxybutynin were pro-
hibited at all times during the study. However, a-adre-
nergic blockers were permitted.
Study Design
Having given their written informed consent to the study,
patients were randomised on a computer-generated block
design ratio (1:1) stratified by centre at the entrance visit
to receive 15 mg trospium chloride three times a day
(TID) or 2.5 mg oxybutynin hydrochloride TID for 12
weeks. On the basis of the symptoms recorded in a sec-
ond micturition diary and on the investigator’sa n d
patient’s impression of the individual’s tolerance of the
study medication, daily doses could be adjusted upward
after four weeks of treatment (at the intermediate visit),
to 90 mg trospium (30 mg TID) or 15 mg oxybutynin
(5 mg TID) for the following eight weeks. In the case of
adverse events (AEs), the increased dosage could be read-
justed to the starting point after one week. Patients
whose symptoms were managed with the standard dose
continued to receive the starting dosage of medication
throughout the study. The study ended for each patient
after 12 weeks of treatment (final visit).
Efficacy and tolerability assessment
For the post hoc analysis, patients in both treatment
groups were stratified to subgroups according to “dose
adjustment” or “no dose adjustment”.
The primary efficacy variable for the current analysis -
as for the parent study - was the absolute reduction in
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last week before the entrance visit) with those of treat-
ment week 12 (i.e., the last week before the final visit).
This quantitative symptom change was calculated from
the patients’ 7-day micturition diaries, which had been
completed by each patient before randomisation and at
treatment week 4 and 12. The intensity of dry mouth,
one of the secondary efficacy variables in the parent
study, was recorded on an ordinal scale (none, mild,
moderate,o rsevere) and also evaluated from the
entrance visit to the intermediate and final visits.
Tolerability was assessed by evaluating the sponta-
neously reported adverse events, and discontinuations in
the subgroups. The association between AEs and treat-
ment was based on physician-assessed causality.
All other efficacy and tolerability assessments con-
ducted in the parent study were described there [13].
Statistical Analysis
The post hoc inferential analysis was performed using the
full analysis set (FAS) of the parent study comprising all
participants who belonged to the safety population (all
patients who were exposed to study medication at least
once) and for whom any post-randomisation efficacy
data were available. All statistical analyses were descrip-
tive. As normal distribution of the parameters of interest
could not be assumed for between-group comparisons,
we used the Wilcoxon rank sum test (van Elteren proce-
dure), stratified by study centre for continuous variables.
The Hodges-Lehmann point estimator (HLest)w a su s e d
as a nonparametric estimator. Interval estimates were
provided in the form of nonparametric 2-sided 95% CI.
The distributions of the observed data are presented by
median, quartiles, minimum, and maximum.
Results
The population of the current analysis, which corre-
sponds to the safety population of the parent study,
included 828 patients (49.9%) randomised to trospium
chloride 45 mg/d and 830 patients (50.1%) randomised
to oxybutynin 7.5 mg/d at 153 urological centres in Ger-
many. After four weeks, 29.2% (484 of 1658) had their
dose adjusted to the permitted increased (i.e., doubled)
dose: 31.5% (261 of 828) of patients in the trospium
group, and in 26.9% (223 of 830) of patients in the oxy-
butynin group. After one week, however, 10.1% (49 of
484) of them (19 in the trospium group and 30 in the
oxybuytnin group) had subsequent dose readjustments
that returned them to the standard starting dose until
the end of treatment.
The FAS population comprised 1608 patients (TC:
810; OXY: 798). No post-randomisation data were avail-
able for 50 patients: 18 (2.2%) in the TC-group and 32
(3.9%) in the OXY-group. Patient demographics revealed
no clinically relevant differences between the treatment
groups. The mean (SD) age of patients was 61.3 (12.17)
years (median: 63 years; range: 20-91 years), 90.3% (n =
1452) were women. Other patient demographics and
characteristics were previously reported [13].
Urge incontinence episodes
Treatment with either trospium chloride or oxybutynin
reduced the total number of UUI episodes per week in
the patient population selected by the defined in- and
exclusion criteria. Table 1 lists the results of the
patients’ diaries.
In the FAS set, the baseline values of UUI episodes
per week (median and mean values) of the “dose adjust-
ment” subgroups were slightly higher than the baseline
values of the “no dose adjustment” subgroups in both
treatment groups, with the only exception concerning
the baseline median values in the oxybutynin “dose
adjustment” subgroup. Until the intermediate visit all
patients received the standard dose of the relevant medi-
cation. At the intermediate visit the patients who ful-
filled the criteria for dose adjustment still suffered from
a higher number of weekly UUI episodes compared to
those patients who needed no dose adjustment. At the
final visit the absolute changes in weekly UUI episodes
from baseline to week 12 (primary endpoint) showed no
relevant differences between the “dose adjustment” sub-
groups and the “no dose adjustment” subgroups in both
treatment groups. Figure 1 illustrates median changes in
weekly UUI episodes at each visit for both treatment
groups and all subgroups. In the FAS the median
change was -11.00 in the “no dose adjustment” TC-sub-
group and -10.58 in the “dose adjustment” TC-sub-
group; in the oxybutynin treatment group the median
change was -10.00 in the “no dose adjustment” sub-
group and -9.00 in the “dose adjustment” subgroup.
There was no indication whatsoever of a significant dif-
f e r e n c eb e t w e e nt h es u b g r oups ("no dose adjustment”
and “dose adjustment”) in terms of this change neither
in the trospium group (P = 0.249) nor in the oxybutynin
group (P = 0.349). This is also obvious from the corre-
sponding non-parametric estimator (HLest)f o rt h ed i f -
ference between both subgroups and the corresponding
95% CI.
Intensity of mouth dryness
The percentage of patients without mouth dryness was
comparable between the treatment groups at baseline
(trospium: 46.8% [257 of 549; “no dose adjustment"]/
49.2% [119 of 242; “dose adjustment"] versus oxybuty-
nin: 45.6% [262 of 575]/45.6% [88 of 193]). At the final
visit, the percentage of patients reporting no dry mouth
was 19.5% (107 of 549) in the “no dose adjustment” TC-
subgroup versus 13.2% (32 of 242) in the “dose
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“no dose adjustment” OXY-subgroup versus 4.7% (9 of
193) in the “dose adjustment” OXY-subgroup.
At week 4 and 12, the increase in “dry mouth” inten-
sity was significantly lower (P < 0.001) in the trospium
groups than in the oxybutynin groups. The percentage
of patients who experienced worsening of dry mouth
from baseline to end of study was 57.0% (138 of 242) in
the “dose adjustment” TC-subgroup versus 70.5% (136
of 193) in the “dose adjustment” OXY-subgroup, and
47.7% (262 of 549) in the “no dose adjustment” TC-sub-
group versus 62.4% (359 of 575) in the “no dose adjust-
ment” OXY-subgroup (Figure 2). Thus, patients of both
dose adjusted subgroups experienced an approximately
10% higher rate of worsening of mouth dryness than
patients of the respective “no dose adjustment” groups
a tt h ee n do fs t u d y .T h ed i f ferences between the sub-
groups were significant for the time period between the
intermediate (i.e., time of dose escalation) and the final
visit (worsening for TC: 43.4% [105 of 242] in the “dose
Table 1 Changes in UUI episodes per week by dose adjustment in the TC-treatment group and the OXY- treatment
group (FAS)
Trospium chloride Oxybutynin













N 546 240 575 192
Mean ± SD 20.1 ± 17.6 22.2 ± 19.58 18.6 ± 16.37 20.8 ± 18.41
Median 14.0 15.0 14.0 13.0
Range 0.0 - 107.0 4.0 - 99.0 0.0 - 120.0 0.0 - 90.0
Intermediate visit
N 531 241 561 193
Mean ± SD 7.9 ± 11.97 12.2 ± 16.4 6.5 ± 10.32 13.4 ± 17.68
Median 3.0 6.0 3.0 6.0
Range 0.0 - 67.0 0.0 - 112.0 0.0 - 109.0 0.0 - 83.0
Final visit
N 502 226 534 181
Mean ± SD 5.4 ± 10.42 7.8 ± 12.49 4.4 ± 9.28 6.9 ± 13.42
Median 1.0 3.0 0.0 1.0
Range 0.0 - 64.0 0.0 - 65.0 0.0 - 80.0 0.0 - 100.0
Change from baseline to final visit
N 508 228 537 182
Mean ± SD -14.96 ± 15.063 -14.40 ±
16.346
-14.29 ± 15.673 -13.56 ±
15.982
Median -11.00 -10.58 -10.00 -9.00






[-2.00; 0.00] [-2.00; 1.00]
P-value 0.248989 0.349402
Note: P-values are obtained from the generalised Wilcoxon Rank sum test without stratification for centre.
Figure 1 Changes in UUI episodes per week by dose
adjustment (median values, FAS).
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“no dose adjustment” subgroup, P < 0.001; OXY: 43.5%
[84 of 193] versus 19.5% [112 of 575], P <0 . 0 0 1 ) ,
whereas the analysis of the changes from baseline to the
end of treatment revealed no significant difference
between the “dose adjustment” and the “no dose adjust-
ment” subgroups for both treatment groups (TC:
P = 0.049; OXY: P = 0.071).
Tolerability
The safety population of the parent study comprised
1658 patients. The tolerability assessments of the cur-
rent analysis based on 1609 patients, i.e., all patients of
the safety population minus those patients (n = 49) who
had dose readjustment because of AEs (19 [2.3%] in the
trospium group and 30 [3.6%] in the oxybutynin group).
The main reasons for dose readjustment that were
determined to be definitely, probably, or possibly treat-
ment-related were gastrointestinal disorders, such as dry
mouth (n = 24), nausea (n = 7), and constipation (n =
3). More patients (n = 17) treated with oxybutynin
15 mg/d experienced the most frequent disorder dry
mouth than those receiving trospium 90 mg/d (n = 7).
Most cases of dry mouth were moderate to severe.
Regarding the time period between the intermediate
visit (i.e., the time of dose escalation) and the final visit,
treatment related AEs occurred in 43 out of 809 patients
(5.3%) taking trospium and in 58 out of 800 patients
(7.3%) taking oxybutynin. Hereby, patients of both dose
adjusted subgroups suffered from a slightly higher rate
of AEs possibly related to the study medication than
those of the “no dose adjustment” subgroups (trospium:
9.5% [23 of 242] versus 3.5% [20 of 567], P <0 . 0 0 1 ;
oxybutynin: 10.9% [21 of 193] versus 6.1% [37 of 607],
P = 0.026). However, this fact did not lead to a higher
rate of study discontinuations in the dose adjusted sub-
groups, neither in the TC-subgroup (5.4% [13 of 242] in
the “dose adjustment” subgroup versus 5.1% [29 of 567]
in the “no dose adjustment” subgroup, P = 0.880) nor in
the OXY-subgroup (6.2% [12 of 193] versus 6.1% [37 of
607], P = 0.951) regarding the same time interval.
Treatment-related AEs were typically anticholinergic
in nature, including dry mouth, constipation, nausea,
dyspepsia, and diarrhoea. Full details of the tolerability
assessments based on the data from the parent study
were described previously [13].
Discussion
This post hoc analysis based on the first randomised,
controlled, double-blind study performed to evaluate the
use of flexible-dose regimen of trospium chloride in
patients with UUI [13]. The current analysis of bladder
diary variables from the parent phase IIIb trial shows
that dose escalation of either trospium or oxybutynin
increased reduction in UUI episodes in the randomised
patient population studied. At the intermediate visit the
patients who received dose adjustment still had suffered
from a higher number of weekly UUI episodes com-
pared to the “no dose adjustment” subgroups. This indi-
cates that there are really a certain proportion of OAB-
patients (approximately 30% in the trospium group)
who might profit from a higher dosage for a better
treatment success. At the end of study, no relevant dif-
ferences in treatment success between the dose adjusted
and the “no dose adjustment” subgroups could be
found, indicating that the total number of weekly UUI
Figure 2 Changes in intensity of dry mouth by dose adjustment (%, FAS).
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escalation by the end of treatment than in patients trea-
ted with the standard dosage.
The standard doses of trospium and oxybutynin
applied in this study are defined in the respective Sum-
mary of Product Characteristics (SPC) and are com-
monly used in general practice. However, the flexible
dosing strategy allowed in this study reflects real-life use
[11], and permits treatment to be tailored to patients’
individual needs based on their individual responses to
the drug. To approximate clinical practice, the flexible
dosing design of the study allowed the investigator
together with the patient to decide whether to increase
the dose or to remain the starting dose by the end of
treatment. This decision was based on the patient’s mic-
turition diary and the subjective feeling of side effects.
Only 29.2% of patients (484 of 1658) required increased
doses after four treatment weeks. This suggests that the
recommended dosage regimens are adequate for most
patients with OAB. On the other hand, it shows that
dose escalation can really improve the therapeutic out-
come of anticholinergic therapy. The flexible-dosing
design of the parent study therefore reflects how OAB
might be successfully managed in clinical practice. Opti-
mal treatment of OAB should be individualised, consid-
ering the patient’s comorbidities and concomitant
medications, and the pharmacological profiles of the dif-
ferent drugs, as recommended in international guide-
lines for OAB therapy [1-4]. The goal of UUI therapy is
simply to get the patient as dry as possible. If the pri-
mary care physician has the possibility of flexible dosing
to facilitate meeting the patient’s goal, it offers him a
real chance of greater improvements in patient’ss y m p -
toms and quality of life.
Adjusting dosage is indeed a common practice for sev-
eral anticholinergic drugs [6-10]. Recent studies with
extended-release oxybutynin [14-17], darifenacin [18],
solifenacin [19], and fesoterodine [20,21] suggest that
reduction of urinary urge and total incontinence epi-
sodes may be improved significantly with a flexible dos-
ing strategy.
Improved efficacy associated with dose escalation has
also been demonstrated in patients with neurogenic
detrusor overactivity [22] treated with trospium chloride
[12] or oxybutynin [23,24].
However, to optimize the therapeutic index, improve-
ments in efficacy by using flexible dosing must be
balanced by gains in safety and tolerability. By virtue of
their mechanism of action, antimuscarinics commonly
interact with muscarinic receptors throughout the body,
thereby affecting a variety of physiological functions
[25]. A somewhat higher rate of AEs and mouth dryness
in the dose adjusted subgroups of both treatment arms
could be detected only by the inferential analysis of the
present study. However, both events did not lead to a
higher rate of study discontinuations, neither in the
trospium nor in the oxybutynin subgroups. The results
of the above mentioned dose titration studies support
this finding, indicating that patients are willing to toler-
ate a certain degree of dry mouth and AEs to reach the
optimal balance between continence and side effects
[8,9,21].
Regarding the rate of AEs in the subgroups with
adjusted daily doses it is remarkable that the adjusted
daily dose of OXY corresponds to the recommended
maximum daily dose approved by the regulatory
authorities.
Conclusions
This post hoc analysis evaluating the efficacy and toler-
ability of trospium chloride demonstrated that urinary
frequency and urge incontinence can be reduced signifi-
cantly with a flexible dosing strategy. Dose adjustment
may improve the therapeutic outcome in some patients,
facilitating the definite balance between the efficacy and
anticholinergic side effects such as dry mouth. In com-
parison to the adjusted dose of oxybutynin which is offi-
cially approved, the adjusted dose of trospium was
proven to be at least as well tolerated, safe and efficient.
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